Table 2.
The clinical characteristics and leukocyte count and differential of young children with COVID-19.
| Median (IQR) | |||
|---|---|---|---|
| Healthy young children | Healthy children with COVID-19 | P-value | |
| (n = 31) | (n = 16) | ||
| Age (Y) | 4 (2–6) | 6 (3–7) | |
| Gender (M/F) | 16 (52%)/15 (48%) | 10 (62%)/6 (38%) | |
| Mild case/Severe case | NA | 1 (6%)/15 (94%) | |
| Signs and symptoms at admission | |||
| Fever | NA | 6 (38%) | |
| Cough | NA | 12 (75%) | |
| Sputum | NA | 0 | |
| Shortness of breath | NA | 1 (6%) | |
| Diarrhea | NA | 0 | |
| Treatment | |||
| Antibiotic treatment | NA | 10 (62%) | |
| Antiviral treatment | NA | 10 (62%) | |
| hormone therapy | NA | 1 (6%) | |
| Ventilation | |||
| Non-invasive (face mask, etc) | NA | 1 (6%) | |
| Mechanical ventilation | NA | 0 | |
| Discharged | NA | 16 (100%) | |
| WBC, ×109/L | 6.9 (6.1–8.1) | 5.6 (5.2–6.2) | 0.007 |
| Lymphcyte, % | 51 (42–58) | 47 (33–59) | 0.239 |
| Monocyte,% | 6.7 (5.5–8.0) | 8.7 (7.3–11.3) | 0.027 |
| Neutrophil, % | 38 (33–46) | 40 (26–65) | 0.282 |
| Eosinophil, % | 2.1 (0.9–4.5) | 2.6 (1.3–5.2) | 0.646 |
| Basophil,% | 0.5 (0.2–0.7) | 0.4 (0.3–0.5) | 0.741 |
| Lymphcyte, ×109/L | 3.4 (2.5–4.6) | 2.5 (2.2–3.3) | 0.008 |
| Monocyte, ×109/L | 0.46 (0.41–0.67) | 0.51 (0.45–0.57) | 0.696 |
| Neutrophil, ×109/L | 2.6 (2.1–3.0) | 3.0 (2.0–4.1) | 0.286 |
| Eosinophil, ×109/L | 0.15 (0.06–0.32) | 0.15 (0.04–0.29) | 0.572 |
| Basophil, ×109/L | 0.03 (0.02–0.05) | 0.02 (0.01–0.04) | 0.673 |
P-values indicate differences between young children with COVID-19 and healthy young children. P < 0.05 was considered statistically significant.